Figures computed from official regulatory filings — .
Ownershipinsiders 22.06% · institutions 46.78%
In EUR · as of Oct 26, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for MAAT PHARMA only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.
Market information source · Oct 26, 2026
Open-market timeline · full history
13 buys38 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| HERVE AFFAGARDtrack record | Buy | $6.5K | conv 46 |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $185.7K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $423K | Unusual size | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $116.3K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $152.4K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $511K | Unusual size | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $101.7K | Unusual size | AMF |
| SENDA BOUCHRARA | Buy | $10.4K | conv 66First in 12mo | AMF |
| HERVE AFFAGARDtrack record | Buy | $1.7K | conv 55First in 12mo | AMF |
| BPIFRANCE INVESTISSEMENT SAStrack record | Award | $1.7M | AMF |
| BPIFRANCE INVESTISSEMENT SAStrack record | Award | $5.4M | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $866.8 | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $4.3K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $386.1 | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $3.4K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $3.3K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $3.1K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $3.2K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $11.1K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $13.6K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $7.8K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $4.5K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $4.6K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $3.4K | AMF |
| SEVENTURE PARTNERS société anonyme a directoire | Sell | $103.8K | AMF |